Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
The two have worked together in Asia since 2003, and Bayer has separate agreements with the market-expansion contractor covering Thailand, China and Cambodia under which DKSH handles importation, regulatory clearance and distribution.
For DKSH, the latest Bayer deal follows Asia-focused agreements with Sanofi ($SNY), Pfizer ($PFE) and GlaxoSmithKline ($GSK), reflecting the company's growing capabilities in healthcare, DKSH Singapore General Manager Lina Chua said.
"Our expertise and quality in healthcare distribution optimally complements Bayer's marketing and sales expertise for high-quality products," Chua said in a statement. "Through our combined strengths, both companies will be able to expand and grow in the market."
DKSH has been expanding its offerings around the continent over the past year, getting into contract manufacturing and closing bolt-on acquisitions to grow its footprint. In June, DKSH opened a 14,000-square-foot South Korean facility to distribute its clients devices, drugs and medical supplies in the country's swelling market.
In the first half of the year, DKSH grew its revenue 14.3% to $5.1 billion. The company operates 150 facilities across 13 countries.
- read DKSH's announcement